Cancer patients with potential eligibility for vascular endothelial growth factor antagonists use have an increased risk for cardiovascular diseases comorbidities

BACKGROUND: Recent studies have reported the prevalence of cardiovascular diseases (CVDs) among cancer patients following the use of the vascular endothelial growth factor (VEGF) signaling inhibitors. However, data for patients with a history of cancer before active cancer treatment are lacking. Thi...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Fei, Hidru, Tesfaldet H., Gao, Ruiyuan, Lin, Yajuan, Liu, Ying, Fang, Fengqi, Liu, Jiwei, Li, Huihua, Yang, Xiaolei, Xia, Yunlong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2020
Materias:
ORIGINAL PAPERS: Epidemiology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7012358/
https://www.ncbi.nlm.nih.gov/pubmed/31584518
http://dx.doi.org/10.1097/HJH.0000000000002277

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7012358/
https://www.ncbi.nlm.nih.gov/pubmed/31584518
http://dx.doi.org/10.1097/HJH.0000000000002277

Ejemplares similares